Sulfasalazine and Stereotactic Radiosurgery for Recurrent Glioblastoma
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This study evaluates the safety associated with the addition of sulfasalazine to stereotactic
radiosurgery for recurrent glioblastoma. Sulfasalazine is a potential tumor selective
radiosensitizer.
Phase:
Phase 1
Details
Lead Sponsor:
Haukeland University Hospital
Collaborators:
Helse Stavanger HF Northwell Health Norwegian Cancer Society University of Bergen Weill Medical College of Cornell University